AIMT News and Press, Aimmune Therapeutics Inc. From 05/12/20

Genfit SA (NASDAQ: GNFT )  -67%  after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will participate in a fireside chat at the RBC Capital Markets 20...

Image source: The Motley Fool. Aimmune Therapeutics Inc   (NASDAQ: AIMT) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading

Aimmune Therapeutics, Inc. (AIMT) Q1 2020 Earnings Conference Call May 11, 2020 16:30 ET Company Participants DeDe Sheel - Vice President, Investor Relations Jayson Dallas - President & Chief Executive Officer Andrew Oxtoby - Chief Commercial Officer Eric Bjerkholt - Chief ...

Aimmune Therapeutics (NASDAQ: AIMT ): Q1 Non-GAAP EPS of -$1.03 beats by $0.15 ; GAAP EPS of -$1.34 misses by $0.16 . Revenue of $0.58M misses by $0.76M . Press Release More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

Continues to be launch ready for PALFORZIA TM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash equivalents and investments on-hand and implementing numerous ca...

COVID-19 Is Distracting Investors from an Amazing Market Opportunity While the world remains hyper-focused on COVID-19 as the biggest healthcare challenge of the past century, it is perhaps easy to overlook progress being made to treat more mundane (yet far more durable) medical problems. ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for t...

Aimmune Therapeutics ( AIMT ) was a stock I followed and invested in and also recommended to my subscribers before the approval. The stock did double over a period of 6 months, however, there were some jittery moments right before Palforzia’s (AR101) approval with unscheduled delays and...

On March 16, Aimmune Therapeutics (NASDAQ: AIMT) announced that the first patients in the U.S. had begun treatment with its recently approved immunotherapy for peanut allergies, Palforzia. On the same day, investors learned that the U.S. Food and Drug Administration (FDA) had questions ...